Month: November 2011

The bars and restaurants of the province of Buenos Aires shall include in their letters of menu legend “excessive salt consumption is harmful to health” and will also be required to make available to customers dietary with low content of sodium salt

Is because thus had before it it a law that sanctioned the Buenos Aires legislature, which provides for fines ranging from 300 to 5,000 pesos, prior warning of the implementing authority, and the disqualification of the establishment up to 180 days in the event of recidivism.

The project of the front for victory Viviana Arcidiácono Senator search “prevent disease, improve the quality of life of citizens and save for future medical expenses,” according to noted legislator to Radio 10.

As he argued, “it is estimated that if salt was halved, be they saved from death by this cause two million and a half people each year in the world”, by which he deduced that “healthy reduce the excessive consumption of salt in food is essential for good health”.

In this regard, explained that the need to implement the legend in the menus “lies in the importance of generating some impact on consumers and create a collective awareness of the risks of consuming too much sodium”.

While the possibility of dietary salt low sodium, “tries to kick off a modification in the food culture of the society, learning to consumers of the existence of a healthier product and that would not alter the taste or predilection of these

“

Consulted on the “protectionist” role of the State before the adoption of this regulation, Arcidiácono considered that “it is not the State cares that generates preventive rules”. “We have to make a change in culture, that is done with information” secured.

Havana, 25 nov (EFE).-United Kingdom apply in the coming weeks a clinical trial of a therapeutic vaccine against lung cancer advanced, CIMAvax-EGF, created by scientists from the center of Molecular Immunology of Havana in Cuba, today confirmed to Efe sources.

The study has been approved by the regulatory agency of United Kingdom after the recent authorization of a multinational, multicenter clinical trial for vaccine Protocol, according to a source of the marketer CIMAB S.A., exclusive representative of the center of Molecular Immunology (CIM) reported today to Efe.

According to the source, in a week or two will be included the first British patient in study

It is also expected next clinical trials in countries such as Australia, Thailand and Malaysia.

Cuban medicine was developed after 15 years of research by scientists at the CIM, who believe that the same principle of the drug could be used in the treatment of oncological illnesses.

According to Cuban experts the drug may not prevent disease but allows you to control advanced cancer to generate antibodies against proteins that trigger the slippage in the processes of proliferation cell.

Membership includes protein P-64 K of the membrane and epidermal growth factor, obtained through recombinant.

With the name commercial CIMAVAX-EGF, the vaccine has been applied with good results to more than 1,000 patients in Cuba, where su record health was conducted in June 2008.

The product was also already registered in Peru and is in the process of registration in other countries of the region, such as Colombia, Brazil, Paraguay, Ecuador and Argentina.

The Director of the project, Gisela Gonzalez, said last January that the vaccine is safe, does not cause severe effects and increases the life expectancy of the patient, with a good quality.

Cuban media have stressed that CIMAVAX-EGF is the first therapeutic vaccine against cancer lung progress registered in the world.

According to data from the World Health Organization, cancer is the leading cause of mortality worldwide, and the lung is one of the of greatest incidence.

It is estimated that in 2008 cancer 7.6 million people died, figure that will rise up to eleven million in 2030. EFE

Havana, 25 nov (EFE).-United Kingdom apply in the coming weeks a clinical trial of a therapeutic vaccine against lung cancer advanced, CIMAvax-EGF, created by scientists from the center of Molecular Immunology of Havana in Cuba, today confirmed to Efe sources.

The study has been approved by the regulatory agency of United Kingdom after the recent authorization of a multinational, multicenter clinical trial for vaccine Protocol, according to a source of the marketer CIMAB S.A., exclusive representative of the center of Molecular Immunology (CIM) reported today to Efe.

According to the source, in a week or two will be included the first British patient in study

It is also expected next clinical trials in countries such as Australia, Thailand and Malaysia.

Cuban medicine was developed after 15 years of research by scientists at the CIM, who believe that the same principle of the drug could be used in the treatment of oncological illnesses.

According to Cuban experts the drug may not prevent disease but allows you to control advanced cancer to generate antibodies against proteins that trigger the slippage in the processes of proliferation cell.

Membership includes protein P-64 K of the membrane and epidermal growth factor, obtained through recombinant.

Under the brand name of CIMAVAX-EGF, the vaccine was applied successfully to more than 1,000 patients in Cuba, where his health registration was conducted in June 2008.

The product was also already registered in Peru and is in the process of registration in other countries of the region, such as Colombia, Brazil, Paraguay, Ecuador and Argentina.

The Director of the project, Gisela Gonzalez, said last January that the vaccine is safe, does not cause severe effects and increases the life expectancy of the patient, with a good quality.

Cuban media have stressed that CIMAVAX-EGF is the first therapeutic vaccine against cancer lung progress registered in the world.

According to data from the World Health Organization, cancer is the leading cause of mortality worldwide, and the lung is one of the of greatest incidence.

It is estimated that in 2008 of cancer 7.6 million people died, figure that will rise up to eleven million in 2030.

According to Cuban experts, the drug may not prevent disease but allows you to control advanced cancer to generate antibodies against proteins that trigger the slippage in the processes of cell proliferation. EFE / file

.